In hemophilia A and autoantibody inhibitor patients: the factor VIII A2 domain and light chain are most immunogenic.
Factor VIII (fVIII) is a protein cofactor essential for blood coagulation, and it binds in the factor Xase complex to factors IXa, X, and phospholipid. In about 30% of severe hemophilia A patients, treatment with fVIII leads to production of anti-fVIII antibodies. Anti-fVIII autoantibodies also rarely appear in normal individuals. Those antibodies that inactivate fVIII (inhibitors) prevent optimal fVIII therapy. Inhibitor epitopes were previously localized to the fVIII A2, A3, and C2 domains and to an acidic amino acid region between A1 and A2. Such anti-fVIII antibodies interfere with fVIII binding to components of the factor Xase complex and prevent blood coagulation. When total anti-fVIII titers were determined for each fVIII domain in 43 inhibitor plasmas by immunoprecipitation (IP) and inhibitor neutralization assays, the anti-light chain (LCh) antibody titer was highest, anti-A2 was intermediate, and anti-A1 and anti-B were low. The relative immunogenicity of the fVIII domains in hemophilic and autoantibody inhibitor patients was similar.
Scandella
D H
DH
Department of Immunology, American Red Cross, 15601 Crabbs Branch Way, Rockville, MD 20855, USA. scandell@usa.redcross.org
Nakai
H
H
Felch
M
M
Mondorf
W
W
Scharrer
I
I
Hoyer
L W
LW
Saenko
E L
EL
D000911:Antibodies, Monoclonal; D001323:Autoantibodies / Q000097:blood*; D001777:Blood Coagulation; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000737:chemistry* / Q000276:immunology*; D006467:Hemophilia A / Q000097:blood* / Q000276:immunology; D006801:Humans; D046911:Macromolecular Substances; D009500:Neutralization Tests; D010446:Peptide Fragments / Q000276:immunology; D011994:Recombinant Proteins / Q000737:chemistry / Q000276:immunology
D000911:Antibodies, Monoclonal; D001323:Autoantibodies; D046911:Macromolecular Substances; D010446:Peptide Fragments; D011994:Recombinant Proteins; D005169:Factor VIII